Onconova Therapeutics Inc. closed its previously announced$5.2 million stock sale.
The Newtown,Pa., biopharmaceutical company, and which is developing cancer therapies,sold 2.48 million shares of its common stock at $2.10 per share.
Onconova (NASDAQ: ONTX) plans to exhaust the proceeds from the financing to further advance its lead new drug candidate, rigosertib, and which it is developing to treat patients with tall risk Myelodysplastic Syndromes or MDS. MDS — considered a type of cancer — can occur…
Source: bizjournals.com